HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
Wells Fargo Downgrades Sangamo, Cites Removal of Key Year-end Catalyst
Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight, Announces $1 Price Target
Sangamo Therapeutics Analyst Ratings
RBC Capital Downgrades Sangamo Therapeutics to Sector Perform, Lowers Price Target to $2
Sangamo Therapeutics Analyst Ratings
Truist Securities Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $7
Sangamo Therapeutics Analyst Ratings
H.C. Wainwright Reaffirms Their Buy Rating on Sangamo Biosciences (SGMO)
Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
Wedbush Lowers Sangamo Therapeutics' Price Target to $10 From $16, Keeps Outperform Rating
No Data